The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S.

Leqembi (lecanemab) has won marketing authorization in the European Union for the treatment of certain adults with early Alzheimer’s disease, making it the first therapy that targets an underlying ...